KR970707076A - 금속단백질 분해효소 억제제(Metalloproteinase Inhibitors) - Google Patents

금속단백질 분해효소 억제제(Metalloproteinase Inhibitors)

Info

Publication number
KR970707076A
KR970707076A KR1019970702933A KR19970702933A KR970707076A KR 970707076 A KR970707076 A KR 970707076A KR 1019970702933 A KR1019970702933 A KR 1019970702933A KR 19970702933 A KR19970702933 A KR 19970702933A KR 970707076 A KR970707076 A KR 970707076A
Authority
KR
South Korea
Prior art keywords
alkyl
group
propyl
hydroxy
isobutyl
Prior art date
Application number
KR1019970702933A
Other languages
English (en)
Inventor
레이몬드 포올 벡케트
마아크 위타커
앤드류 밀러
피온나 미첼 마틴
Original Assignee
포올 리틀우드
브리티쉬 바이오테크 파마슈티칼스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포올 리틀우드, 브리티쉬 바이오테크 파마슈티칼스 리미티드 filed Critical 포올 리틀우드
Publication of KR970707076A publication Critical patent/KR970707076A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F25—REFRIGERATION OR COOLING; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS; MANUFACTURE OR STORAGE OF ICE; LIQUEFACTION SOLIDIFICATION OF GASES
    • F25B—REFRIGERATION MACHINES, PLANTS OR SYSTEMS; COMBINED HEATING AND REFRIGERATION SYSTEMS; HEAT PUMP SYSTEMS
    • F25B39/00—Evaporators; Condensers
    • F25B39/02—Evaporators
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F28—HEAT EXCHANGE IN GENERAL
    • F28F—DETAILS OF HEAT-EXCHANGE AND HEAT-TRANSFER APPARATUS, OF GENERAL APPLICATION
    • F28F27/00—Control arrangements or safety devices specially adapted for heat-exchange or heat-transfer apparatus
    • F28F27/02—Control arrangements or safety devices specially adapted for heat-exchange or heat-transfer apparatus for controlling the distribution of heat-exchange media between different channels

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Polyethers (AREA)
  • Materials For Photolithography (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)

Abstract

R4가 폴리에테르기임을 기본 특징으로 하는 다음 일반식(Ⅰ)의 화합물은 수용성 매트릭스 금속단백질 분해효소 억제제이다.

Description

금속단백질 분해효소 억제제(Metalloproteinase Inhibitors)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 다음 일반식(Ⅰ)의 화합물, 또는 이의 염, 수화물이나 용매화물 :
    상기 식에서, X는 -CO2H 또는 -CONHOH기이고; R1은 수소, C1-C6알킬, C2-C6알켄일, 페닐, 치환페닐, 페닐(C1-C6알킬), 헤테로시클일, 치환 헤테로시클일, 헤테로시클일(C1-C6알킬), 치환 헤테로시클일(C1-C6알킬) 또는 BSOnA기이고, 여기서 n는 0, 1 또는 2이고 B는 수소 또는 (C1-C6)알킬, 페닐, 치환페닐, 헤테로시클일, C1-C6아실, 펜아실 또는 치환 펜아실기이고, A는 C1-C6알킬; 아미노; 보호 아미노; 아실아미노; OH; SH; C1-C6알콕시; C1-C6알킬아미노; C1-C6알킬티오; 아릴 (C1-C6알킬); 아미노(C1-C6알킬); 히드록시(C1-C6알킬), 머캅토 (C1-C6알킬) 또는 카르복시 (C1-C6알킬)(여기서 아미노-, 히드록시-, 머캅토- 또는 카르복실-기는 임의로 보호되고 카르복실기는 아미드화 된다); 또는 말레이미도, 석신이미도, 나프탈이미도, 2, 3-디하이드로-1, 3-디옥소-1H-벤즈〔d, e〕이소퀴놀-2-일, 카르바모일, 모노(저급 알킬)카르바모일 디(저급 알킬)카르바모일, 디(저급 알킬)아미노, 카르복시-저급 알카노일아미노, 피롤리디노 또는 몰포리노에 의하여 치환된 저급 알킬이다; R2는 C1-C12알킬, C2-C12알켄일, C2-C|12알킨일, 벤질 시클로알킬(C1-C6알킬)-, 시클로알켄일(C1-C6알킬)-, 페닐(C1-C6알킬)O(C1-C|6알킬)-, 또는 헤테로아릴(C1-C6알킬)O(C1-C6알킬)-기이고, 이들 중 어느 하나는 C1-C6알킬, C1-C6알콕시, 할로 또는 시아노(-CN)에 의하여 임의로 치환될 수 있다; R3는 기능기가 존재하면, 예를 들어 아미노기의 아실화와 카르복실기의 아미드화에 의하여 보호될 수 있는 자연 발생 아이노산의 측쇄; 또는 -CR6R7R8기(여기서 R6, R7와 R8은 각각 독립적으로 수소, (C1-C6) 알킬, (C2-C6) 알켄일, (C2-C6) 알킨일, 페닐(C1-C6) 알킬, 할로겐, -CN, -CO2H, (C1-C4)퍼플루오로알킬, -CO2(C1-C6)알킬 또는 히드록시, 할로겐, -CN, -CO2H, CO2(C1-C6)알킬, -CONH2, -CONH(C1-C6)알킬, -CONH(C1-C6알킬)2, -CHO, -CH2OH, (C1-C4)퍼플루오로알킬, -O(C1-C6) 알킬, -S(C1-C6)알킬, -SO(C1-C6)알킬, -SO2(C1-C6) 알킬, NO2, -NH2, -NH(C1-C6) 알킬, -N(C1-C6) 알킬)2, -NHCO(C1-C6) 알킬, (C1-C6) 알킬, (C2-C6)알켄일, (C2-C6)알킨일, (C3-C8)시클로알킬, (C4-C8)시클로알켄일, 페닐 또는 벤질에서 독립적으로 선택한 하나 또는 그 이상의 치환기에 의하여 임의로 치환된 페닐이나 헤테로아릴기이고, R6와 R7은 이들에 결합되는 탄소원자와 함께 3∼8 원환 시클로알킬 또는 5∼6 원환 헤테로고리환을 형성하거나, R6, R7과 R8은 이들에 결합되는 탄소원자와 함께 이 고리환(예를들어 아디만틸)을 형성한다. R4는 식 -(Z-O)n-Z기, 여기서 Z는 하나 또는 그 이상의 비-인접 S와/또는 N원자에 의하여 임의로 치환된 직쇄 또는 분지쇄 C1-6알킬이고, n는〉1정수이고, R4기에서 원자의 비연속 선형 배열은 〉12이다) 또는, 하나 또는 그 이상의 비-인접 S와/또는 N원자에 의하여 임의로 차단되는 직쇄 또는 분지쇄 C2-6알킬기, (여기서, 기는 식 -(Z)p-(OZ)q의 최소한 둘의 치환기에 의하여 치환되고, Z는 하나 또는 그 이상의 비-인접 S와/또는 N원자에 의하여 임의로 차단된 직쇄 또는 분지쇄 C1-6알킬이고, p는 0 또는 1이고, q는 1 또는 2이고, R4에서 원자의 비연속 선형배열은〉12이다. R5는 수소 또는 (C1-C6) 알킬기이다.
  2. 제1항에 있어서, 입체화학이, R1과 X기를 갖는 C원자 -S, R2기를 갖는 C원자 -R, R3기를 갖는 C원자 -S인 화합물.
  3. 제1항 또는 제2항에 있어서, R1이 수소, 히드록실, n-프로필 또는 알릴인 화합물.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, R2가 이소-부틸, n-펜틸, n-헥실, n-헵틸, n-노닐, n-데실 또는 벤질옥시프로필인 화합물.
  5. 제1항 내지 제4항 중 어느 한 항에 있어서, R3가 벤질, 이소-부틸, t-부틸 또는 1-플루오로-1-메틸에틸인 화합물.
  6. 제1항 내지 제5항 중 어느 한 항에 있어서, R4가 2-(2-메톡시에톡시메톡시)에틸, 1, 1-디메틸-2-(2-메톡시에톡시메톡시)에틸, 2-(2-에톡시에톡시메톡시)에틸, 2-2-(2-메톡시에톡시)에톡시)에틸, 2-(2-(3-메톡시프로폭시)에톡시)에틸, 3-(2-메톡시에톡시메톡시)프로필, 2, 2-디메틸-3-(2-메톡시에톡시메톡시)프로필, 2-(2-에톡시에톡시)에틸, 3-(2-메톡시에톡시)프로필, 2, 2-디(2-메톡시메틸)프로필과 2, 2-디(2-메톡시메틸)프로필과 2, 2-디(2-메톡시메틸)부틸인 화합물.
  7. 제1항 내지 제5항 중 어느 한 항에 있어서, R4가 2-(2-메톡시에톡시)에틸인 화합물.
  8. 제1항 내지 제7항 중 어느 한 항에 있어서, R5가 수소인 화합물.
  9. 2S-알릴-N'-히드록시-3R-이소부틸-N4-{1S〔2-(2-메톡시-에톡시)에틸카르바모일〕-2. 2-디메틸-프로필} 석신아미드와 이의 염, 용매화물 또는 수화물.
  10. 2S-N1-디히드록시-3R-이소부틸-N4-{1S〔2-(2-메톡시-에톡시메톡시)에틸카르바모일〕-2, 2-디메틸-프로필}-석신아미드, 2S-알릴-N1-히드록시-3R-이소부틸-N4-{1S 〔2-(2-메톡시-에톡시메톡시)에틸카르바모일〕-2-페틸-에틸}-석신아미드, 2S-알릴-N1-히드록시-3R-이소부틸-N4-{1S〔2-(2-메톡시-에톡시메톡시)에틸카르바모일〕-2, 2-디메틸-프로필}-석신아미드, 2S-알릴-N1-히드록시-3R-이소부틸-N4-(1S-{2-〔2-(2-메톡시-에톡시)-에톡시〕에틸카르바모일〕-2, 2-디메틸-프로필}-석신아미드, 2S-알릴-N4-{1S〔2, 2-디-(메톡시에틸)-프로필카르바모일〕-2. 2-디메틸-프로필}-N'-히드록시-3R-이소부틸-석신아미드, 2S-알릴-N4-{1S〔2, 2-디-(메톡시메틸)-부틸카르보모일〕-2, 2-디메틸-프로필}-N1-히드록시-3R-이소부틸-석신아미드), N4-히드록시-2R-이소부틸-N1-{1S-〔2-(2-메톡시-에톡시)-에틸카르바모일〕-2. 2-디메틸-프로필}-3S-(티오펜-2-일-술판일메틸)-석신아미드), N4-히드록시-2R-이소부틸-N1-(1S-{2-〔2-(2-메톡시-에톡시)-에톡시)-에틸카르바모일〕-2, 2-디메틸-프로필}-3S-(티오펜-2-일-술판일메틸)-석신아미드), N4-히드록시-2R-이소부틸-N1-(1S-{2-[2-(2-메톡시-에톡시)-에톡시]-에틸카르바모일}-2, 2-디메틸-프로필)-3S-(티오펜-2-일-술판일메틸)-석신아미드), N1-{1S-〔2, 2-디-(메톡시메틸)-프로필카르바모일〕-2, 2-디메틸-프로필}-N4-히드록시-3R-이소부틸-3S-(티오펜-2-일-술판일메틸)-석신아미드, N4-히드록시-2R-이소부틸-N1-{1S-〔2-(2-메톡시-에톡시)-에틸카르바모일〕-2, 2-디메틸-프로필}-2S-프로필-석신아미드)와 이들의 염, 용매화물 또는 수화물에서 선택한 화합물.
  11. 약학적으로 또는 수의학적으로 수용할 수 있는 담체와 함께, 전술한 항중 어느 한 항에 따른 화합물로 이루어지는 약학적 또는 수의학적 조성물.
  12. 제11항에 있어서, 경구투여용으로 사용하는 조성물.
  13. 제11항 또는 제12항에 있어서, 상기 화합물이 수용성인 조성물.
  14. 다음 일반식(Ⅱ)의 산 또는 이의 활성화 유도체를, 히드록실아민, O-보호히드록실아민이나 N, O-탈보호 히드록실아민 또는 이들의 염과 반응시켜서 하는 X가 히드록삼산기인 제1항에 따른 화합물의 제조방법.
    상기 식에서, R1, R2, R3, R4와 R5는 제1항에서 정의한 바와 같으나 R1, R2, R3, R4와 R5에서 히드록실아민과 강하게 반응하는 어떠한 치환기는 제외한다. O-보호 히드록실아민, N, O-탈보호 히드록실아민 또는 이들의 염은 그들 자신 이러한 반응으로부터 보호될 수 있고, 이때 반응 생성된 히드록삼산기로부터와 R1, R2, R3, R4와 R5의 어떠한 보호 치환기로부터 어떠한 보호기를 제거한다.
  15. 다음 일반식(Ⅳ)의 산 또는 이의 활성화 유도체를 다음 일반식(Ⅴ)의 아민과 커플링시켜서 하는 X가 카르복실산기인 제1항에 따른 화합물의 제조방법 :
    상기 식에서, R1, R2, R3, R4와 R5는 제1항에서 정의한 바와 같으나 R1, R2, R3, R4와 R5에서 커플링 반응에서 강한 반응성을 갖는 어떠한 치환기가 이와 같은 반응에서 그들 자체가 보호될 수 있는 것은 제외되며, R11은 히드록시 보호기를 나타내며, 계속하여 R1, R2, R3, R4와 R5에서 보호기 R11과 어떠한 보호기를 제거한다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702933A 1994-11-26 1995-11-27 금속단백질 분해효소 억제제(Metalloproteinase Inhibitors) KR970707076A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423914.2 1994-11-26
GB9423914A GB9423914D0 (en) 1994-11-26 1994-11-26 Polyether derivatives as metalloproteinase inhibitors
PCT/GB1995/002770 WO1996016931A1 (en) 1994-11-26 1995-11-27 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
KR970707076A true KR970707076A (ko) 1997-12-01

Family

ID=10765035

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702933A KR970707076A (ko) 1994-11-26 1995-11-27 금속단백질 분해효소 억제제(Metalloproteinase Inhibitors)

Country Status (20)

Country Link
US (1) US5866717A (ko)
EP (1) EP0793641B1 (ko)
JP (1) JPH11501288A (ko)
KR (1) KR970707076A (ko)
CN (1) CN1166825A (ko)
AT (1) ATE179165T1 (ko)
AU (1) AU688164B2 (ko)
BR (1) BR9509823A (ko)
CA (1) CA2205972A1 (ko)
CZ (1) CZ159197A3 (ko)
DE (1) DE69509254T2 (ko)
ES (1) ES2131342T3 (ko)
FI (1) FI972198A0 (ko)
GB (1) GB9423914D0 (ko)
HU (1) HUT77221A (ko)
NO (1) NO972379L (ko)
NZ (1) NZ295725A (ko)
PL (1) PL320292A1 (ko)
SK (1) SK65097A3 (ko)
WO (1) WO1996016931A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997015553A1 (fr) * 1995-10-23 1997-05-01 Sankyo Company, Limited Derives de l'acide hydroxamique
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
SI0874830T1 (en) * 1995-12-08 2003-08-31 Agouron Pharmaceuticals, Inc. A metalloproteinase inhibitor, a pharmaceutical composition containing it and the pharmaceutical use and method useful for the preparation thereof
TR199900725T2 (xx) * 1996-10-02 1999-07-21 Novartis Ag Hidroksamik asit t�revleri
US6500983B2 (en) 1996-10-02 2002-12-31 Novartis Ag Hydroxamic acid derivatives
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9707333D0 (en) * 1997-04-11 1997-05-28 British Biotech Pharm Metalloproteinase inhibitors
GB9804504D0 (en) * 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
AR028606A1 (es) * 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
CN1732023A (zh) * 2002-12-27 2006-02-08 血管技术国际股份公司 组合物和使用collajolie的方法
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122359C (ko) * 1964-03-06
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5270326A (en) * 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
CA2073510A1 (en) * 1990-12-03 1992-06-04 Celltech Therapeutics Limited Peptidyl derivatives
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
KR100255203B1 (ko) * 1991-11-08 2000-05-01 가와무라 요시부미 콜라게나제 저해제
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
CA2158352A1 (en) * 1993-03-16 1994-09-29 Michael John Crimmin Hydroxamic acid derivatives as metalloproteinase inhibitors
AU672888B2 (en) * 1993-03-18 1996-10-17 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
ATE182137T1 (de) * 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
HUT74511A (en) * 1994-01-22 1997-01-28 British Biotech Pharm Metalloproteinase inhibitors, pharmaceutical compns. contg. them and process to prepare the said compds.

Also Published As

Publication number Publication date
DE69509254T2 (de) 1999-09-23
GB9423914D0 (en) 1995-01-11
FI972198A (fi) 1997-05-23
CA2205972A1 (en) 1996-06-06
NO972379D0 (no) 1997-05-23
ES2131342T3 (es) 1999-07-16
SK65097A3 (en) 1997-12-10
AU688164B2 (en) 1998-03-05
CZ159197A3 (cs) 1998-02-18
PL320292A1 (en) 1997-09-15
NZ295725A (en) 1998-07-28
US5866717A (en) 1999-02-02
EP0793641B1 (en) 1999-04-21
FI972198A0 (fi) 1997-05-23
DE69509254D1 (de) 1999-05-27
AU3933295A (en) 1996-06-19
JPH11501288A (ja) 1999-02-02
EP0793641A1 (en) 1997-09-10
CN1166825A (zh) 1997-12-03
BR9509823A (pt) 1997-11-04
WO1996016931A1 (en) 1996-06-06
HUT77221A (hu) 1998-03-02
ATE179165T1 (de) 1999-05-15
NO972379L (no) 1997-05-23

Similar Documents

Publication Publication Date Title
KR970707076A (ko) 금속단백질 분해효소 억제제(Metalloproteinase Inhibitors)
RU2333205C2 (ru) Производные бензотиадиазепина, способ их получения и их применение, фармацевтическая композиция, обладающая ингибирующей активностью в отношении переноса желчных кислот в подвздошной кишке
ZA801543B (en) Pharmaceutical heterocyclic compounds and compositions
KR920002627A (ko) α-케토 아미드 유도체
LU91112I2 (fr) Pregabalin, facultativement sous forme d'un sel pharmaceutiquement acceptable.
KR960703858A (ko) 물질 p 길항제로서의 퍼히드로이소인돌 유도체(perhydroisoindole derivatives as substance p antagonists)
ES8607244A1 (es) Procedimiento para la preparacion de derivados de quinolina.
KR870004019A (ko) 퀴놀린 유도체의 제조방법
SE8205698L (sv) N-(4-(3-aminopropyl)aminobutyl-2-(omega-guanidinofettsyra-amido)-2-substituerad-etanamid, salt derav och forfarande for framstellning derav
ES8200645A1 (es) Un procedimiento para la preparacion de un muramildipeptido.
RU97113367A (ru) Производные нейраминовой кислоты, их получение и применение в медицине
KR950011413A (ko) 뉴로텐신에 대해 활성이 있는 치환1-니프틸-3-피라졸카르복사미드. 이의 제법 및 이를 함유하는 약학 조성물
ZA836090B (en) Thieno-thiazole derivatives,processes for preparing these compounds,and pharmaceutical compositions thereof
RU2000119110A (ru) Производные хромана, замещенные по карбоксильной группе, применимые в качестве агонистов бета-3-адренорецептора
KR930021621A (ko) 프로페노일-이미다졸 유도체
KR950008517A (ko) 신규 세팔로스포린계 항생제 및 이의 제조방법
ES8401768A1 (es) Procedimiento de obtener alcaloides bisindolicos.
CA2042112A1 (en) N'-alkyl-spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
KR960704889A (ko) 인돌리진 유도체의 제조방법 (Process for the preparation of indolizine derivatives)
DK1189908T3 (da) Indolcarbazolalkaloider fra en marin strålesvamp
KR910007930A (ko) 15 위치가 치환된 20,21-디노르에버나메닌의 신규한 유도체, 그의 제조 방법 및 신규한 중간체, 약제로서의 그의 용도 및 그를 함유하는 제약 조성물
RU97110155A (ru) Ингибиторы металлопротеиназы
HU894471D0 (en) Process for the preparation of 15-amino-20,21-dinor-eburnamenine derivatives and pharmaceutical compositions containing them
ZA838139B (en) Semicarbazides,process for preparing these,and pharmaceutical compositions thereof
KR910015585A (ko) 신규한 세팔로스포린 화합물과 그의 제조방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid